Graftys SA, a developer of synthetic bone void substitute products, announced it received 510(k) premarket clearance notification from the U.S. Food and Drug Administration for its Graftys Quickset injectable, fast-setting bone void filler, according to a Graftys news release.
The Aix-en-Provence, France-based company now offers a range of resorbable, highly injectable phosphocalcic cements, which includes slower setting Graftys HBS, to address a wide array of clinical needs, according to the release.
Read the Graftys release on Quickset bone filler (pdf).
Recommended OnDemand Webinar